Literature DB >> 9371343

Semiquantitation of cooperativity in binding of vancomycin-group antibiotics to vancomycin-susceptible and -resistant organisms.

D A Beauregard1, A J Maguire, D H Williams, P E Reynolds.   

Abstract

The association of vancomycin group antibiotics with the growing bacterial cell wall was investigated by using the cell wall precursor analog di-N-acetyl-Lys-D-Ala-D-Ala in competition binding experiments. The affinities of the antibiotics for the -D-Ala-D-Ala-containing cell wall precursors of Bacillus subtilis ATCC 6633 (a model for vancomycin-susceptible gram-positive bacteria) and for the -D-Ala-D-Lac-containing cell wall precursors of Leuconostoc mesenteroides (a model for vancomycin-resistant strains of Enterococcus faecium and Enterococcus faecalis) were determined by a whole-cell assay. The binding of strongly dimerizing antibiotics such as eremomycin to the bacterial surface was thus shown to be enhanced by up to 2 orders of magnitude (relative to the binding in free solution) by the chelate effect, whereas weakly dimerizing antibiotics like vancomycin and antibiotics carrying lipid tails (teicoplanin) benefited less (ca. 1 order of magnitude). The affinity measured in this way correlates well with the MIC of the antibiotic, and a consequence of this is that future design of semisynthetic vancomycin-group antibiotics should attempt to incorporate chelate effect-enhancing structural features.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371343      PMCID: PMC164138     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.

Authors:  N E Allen; J N Hobbs; T I Nicas
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics.

Authors:  D A Beauregard; D H Williams; M N Gwynn; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

4.  Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues.

Authors:  N E Allen; D L LeTourneau; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine.

Authors:  G M Sheldrick; P G Jones; O Kennard; D H Williams; G A Smith
Journal:  Nature       Date:  1978-01-19       Impact factor: 49.962

6.  Glycopeptide antibiotics: a mechanism-based screen employing a bacterial cell wall receptor mimetic.

Authors:  J B Rake; R Gerber; R J Mehta; D J Newman; Y K Oh; C Phelen; M C Shearer; R D Sitrin; L J Nisbet
Journal:  J Antibiot (Tokyo)       Date:  1986-01       Impact factor: 2.649

7.  Preparation of biologically active ristocetin derivatives: replacements of the 1'-amino group.

Authors:  T R Herrin; A M Thomas; T J Perun; J C Mao; S W Fesik
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

8.  Conformation of A82846B, a glycopeptide antibiotic, complexed with its cell wall fragment: an asymmetric homodimer determined using NMR spectroscopy.

Authors:  W G Prowse; A D Kline; M A Skelton; R J Loncharich
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

9.  Modifications of the acyl-D-alanyl-D-alanine terminus affecting complex-formation with vancomycin.

Authors:  M Nieto; H R Perkins
Journal:  Biochem J       Date:  1971-08       Impact factor: 3.857

10.  Physicochemical properties of vancomycin and iodovancomycin and their complexes with diacetyl-L-lysyl-D-alanyl-D-alanine.

Authors:  M Nieto; H R Perkins
Journal:  Biochem J       Date:  1971-08       Impact factor: 3.857

View more
  7 in total

1.  Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

Authors:  M Arthur; F Depardieu; P Reynolds; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate.

Authors:  Lan Chen; Deborah Walker; Binyuan Sun; Yanan Hu; Suzanne Walker; Daniel Kahne
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-24       Impact factor: 11.205

3.  A carrier protein strategy yields the structure of dalbavancin.

Authors:  Nicoleta J Economou; Virginie Nahoum; Stephen D Weeks; Kimberly C Grasty; Isaac J Zentner; Tracy M Townsend; Mohammad W Bhuiya; Simon Cocklin; Patrick J Loll
Journal:  J Am Chem Soc       Date:  2012-03-01       Impact factor: 15.419

4.  Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies.

Authors:  Norris E Allen; Deborah L LeTourneau; Joe N Hobbs; Richard C Thompson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Role of murF in cell wall biosynthesis: isolation and characterization of a murF conditional mutant of Staphylococcus aureus.

Authors:  R G Sobral; A M Ludovice; H de Lencastre; A Tomasz
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

6.  Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance.

Authors:  Hannah Piepenbreier; Angelika Diehl; Georg Fritz
Journal:  Nat Commun       Date:  2019-06-21       Impact factor: 14.919

7.  Bacterial Cell Wall Analogue Peptides Control the Oligomeric States and Activity of the Glycopeptide Antibiotic Eremomycin: Solution NMR and Antimicrobial Studies.

Authors:  László Izsépi; Réka Erdei; Anna N Tevyashova; Natalia E Grammatikova; Andrey E Shchekotikhin; Pál Herczegh; Gyula Batta
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.